Important note: Information in this article was accurate in September 2006. The state of the art may have changed since the publication date.
Online medical journals
HIV Treat Bull - Vol. 7, No. 7/8, September 2006
“AIDS Issue” of the British medical journal The Lancet online
The “AIDS Issue” of the British medical journal The Lancet is now online at www.thelancet.com. Many of the articles are available for free, after registering on the site.
The Lancet, Volume 368, Number 9534, 05 August 2006
Contents include many articles, opinion and discussion articles in addition to research papers, including
Primary Research
Department of Ethics
TAG pipeline drugs report: July 2006
Three new reports from TAG were published on-line this week and distributed at the AIDS conference in Toronto.
OSI/TAG report on civil society involvement in TB/HIV
Including six case studies of civil society involvement in TB/HIV advocacy by Agua Buena Human Rights Association (Dominican Republic, El Salvador, Guatemala, Honduras, Jamaica, and Nicaragua), Fundación Mexicana para la Lucha contra el Sida (Mexico), Gender AIDS Forum (South Africa), Salvation (Ukraine), The Shepherd’s Hospice (Sierra Leone), and Yayasan Spiritia (Indonesia).
The report summarises the advocacy activities, lessons learned, and next steps. It was ably written by Jeff Hoover and jointly published by OSI’s Public Health Watch and TAG’s TB/HIV Project.
OSI/TAG report on civil society involvement in TB/HIV
Tuberculosis R&D Investments: A Preliminary Assessment
A documented review of current levels of spending on tuberculosis research and development (R&D) by the top 30 reporting donors, including basic science, research on new tools (diagnostics, drugs, and vaccines), and operational research.
30 respondents reported spending $348 million on TB R&D in 2005, 70% of it by the public sector, 23% by philanthropies (mainly the Gates Foundation, 6.5% by industry (only 4 companies disclosed investments), and 0.5% by multilateral agencies.
$93 million (27% of investment) went to basic research, $15 million (4%) to diagnostics, $67 million (19%) to vaccines, $100 million (29%) to drugs, $48 million (14%) to operational research, and $23 million (7%) unspecified. The report reveals that research spending lags behind targets specified in The Global Plan to Stop TB: 2006-2015 by $700 million per year.
A more complete report will be released at the IUATLD 37th World Conference on Lung Health from 31 October - 4 November 2006.
Tuberculosis R&D Investments: A Preliminary Assessment
2006-09-10
IB060709-07
©2008. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.